Clinical Topics & News

Promising Method to Evaluate Response to Treatment

The use of intravoxel incoherent motion magnetic resonance imaging may be another “valuable imaging tool” to early detect cervical cancer.


 

When patients are diagnosed with cervical cancer at the locally advanced stage, the standard care is concurrent chemoradiotherapy (CCRT). But what if that isn’t the right choice?

Related: Using a Multiplex of Biomarkers to Detect Prostate Cancer

Ineffective treatment is associated with increased toxicity, accelerated tumor growth, and a delay in starting any alternative potentially effective treatment, according to researchers from Nanjing Drum Tower Hospital in China. These researchers suggest a role for intravoxel incoherent motion (IVIM) magnetic resonance imaging (MRI), which is an extension of diffusion-weighted MRI (DWI).

Related: How Much Is Too Much Cancer Screening?

To date MRI has been established as the most effective imaging method in cervical cancer. However, DWI has shown potential as an early predictor based on morphologic, physiologic, and metabolic information. In turn, IVIM imaging, which assesses microscopic changes in diffusion and perfusion, has been used to provide clues to cancers in the head and neck, prostate, breast, and kidney—but not cervical cancer.

In their study, the researchers enrolled 21 patients about to undergo CCRT for advanced cervical cancer. These patients received MR examinations, including IVIM imaging, 1 week before CCRT, 2 and 4 weeks during CCRT, and after 1 week post-CCRT to address the use of IVIM imaging in cervical cancer.

Related: Early Cancer Detection Helps Underserved Women

The IVIM MR imaging showed “dynamic changes” of cervical cancers during treatment, making IVIM parameters possible biomarkers for tumor response following CCRT for cervical cancer. With technological advances the researchers say, IVIM could become “a valuable imaging tool,” in the clinic as well as in cancer research.

Source:

Zhu L, Zhu L, Shi H, et al. BMC Cancer. 2016;16:79
doi 10.1186/s12885-016-2116-5

Recommended Reading

USPSTF Supports Mammography Starting at Age 50
Federal Practitioner
Will VA & DoD Be Part of the Cancer Moon Shot?
Federal Practitioner
Families Perceive Few Benefits From Aggressive End-of-Life Care
Federal Practitioner
False Estradiol Results From Interaction With Fulvestrant
Federal Practitioner
FDA Approves Rescue Drug for Chemotherapy Overdose
Federal Practitioner
VA/DoD to Help Lead New Cancer Initiative
Federal Practitioner
Dronabinol: A Controversial Acute Leukemia Treatment
Federal Practitioner
Using a Multiplex of Biomarkers to Detect Prostate Cancer
Federal Practitioner
Implementation of a Precision Oncology Program as an Exemplar of a Learning Health Care System in the VA
Federal Practitioner
A Systems Engineering and Decision-Support Tool to Enhance Care of Veterans Diagnosed With Prostate Cancer
Federal Practitioner

Related Articles